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Detection of an Intragenic Deletion Expands the
Spectrum of CTSC Mutations in Papillon–Lefe`vre
Syndrome
Thomas Jouary1,2,9, Cyril Goizet3,9, Isabelle Coupry3, Isabelle Redonnet-Vernhet4, Thierry Levade5,
Ingrid Burgelin3, Annick Toutain6, Emmanuel Delaporte7, Claire Douillard8, Didier Lacombe3, Alain Taieb1,2
and Benoıˆt Arveiler3
The Papillon–Lefe`vre syndrome (PLS) is an autosomal recessive disorder. The gene responsible for the disease,
cathepsin C (CTSC), is localized in 11q14.1–q14.21. We performed mutational and functional analyses of CTSC in
two patients affected by this condition. Three previously unreported CTSC mutations were identified. The first
patient had a compound heterozygous status with a p.G386R missense mutation and an intragenic deletion
spanning exons 3–7. Second patient carried a homozygous splice site mutation, p.A253SfsX30. CTSC activity was
undetectable in both patients, thus demonstrating the pathological effect of these mutations. We describe early
evidence of an original intragenic deletion reported in PLS. Since this mutational mechanism could not be
detected by direct sequencing, intragenic deletion has to be specifically investigated using gene dosage analysis
techniques such as quantitative multiplex fluorescent polymerase chain reaction. We consider that this
technique should be performed in patients with apparently homozygous CTSC mutations when one parent
does not carry the expected mutation or is not available for analysis.
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INTRODUCTION
Papillon–Lefe`vre syndrome (PLS) (OMIM 245000) is a rare
autosomal recessive disorder characterized by the association
of palmoplantar keratoderma and periodontitis. Cathepsin C
(CTSC), a lysosomal cysteine protease, plays an essential role
in the activation of serine proteases, particularly leukocyte
elastase and granzymes A and B.
We report hereafter the results of genetic investigations
obtained in two PLS families. The functional consequences of
these mutations were explored using enzymatic assays to
confirm their pathological effect.
RESULTS
Patient 1 exhibited the most interesting findings with the
identification of a compound heterozygous status composed
of two novel mutations. Firstly, the gene sequencing of this
case displayed a missense mutation p.G386R (Figure 1a).
Although this finding was rather suggestive of a homozygous
mutation, sequencing of parents’ DNA revealed a hetero-
zygous p.G386R mutation in her mother but not in her father.
Microsatellite analyses performed in this patient and her
parents allowed us to exclude false paternity and uniparental
isodisomy (data not shown). We therefore suspected the
presence of a concomitant large deletion of CTSC transmitted
by her father on the second allele. A gene dosage analysis
was performed over the entire coding region of CTSC by
quantitative multiplex fluorescent-polymerase chain reaction
(QMF-PCR) technique (Niel et al., 2004). Experimental
conditions were optimized for each exon and validated using
the DNA of healthy controls and of a deleted control
corresponding to a case who carried a previously described
11q14.3 deletion including CTSC (Goizet et al., 2004). The
QMF-PCR analysis demonstrated the presence of a hetero-
zygous intragenic deletion of CTSC involving exons 3–7 both
in patient 1 and her father (Figure 1b and c).
In patient 2, we identified a homozygous splice site
mutation, c.757G4A, affecting a highly conserved residue.
Moreover, this mutation alters the donor splice site at the end
of exon 5 with a predictive score in silico decreasing from
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0.98 to 0 (Splice Site Prediction by Neural Network). This
suggests the absence of intron 5 splicing. Both asymptomatic
parents were shown to be heterozygous for this mutation
(Figure 2).
The functional analyses showed an almost undetectable
level of CTSC activity in the two patients carrying CTSC
mutations confirming their pathological effect (Table 1).
DISCUSSION
More than 50 mutations have been reported so far in PLS.
Missense and nonsense mutations are the most frequent, but
small deletions, insertions and splice site mutations have also
been reported (Selvaraju et al., 2003). The data obtained in
patient 1 are highly remarkable. Indeed, this patient showed
an unreported compound heterozygous CTSC mutation
which associates a p.G386R mutation on the maternal allele
and an intragenic deletion including exons 3–7 on the
paternal allele. The p.G386R mutation affects a glycine
residue, which is highly conserved among species and other
cysteine proteases including cathepsins. The substitution by a
positively charged arginine is therefore probably deleterious.
Additionally, the QMF-PCR analyses showed a 50% reduced
gene dosage of exons 3–7 of CTSC (Figure 1). This intragenic
deletion leads to a truncated protein containing only the first
two exons of the gene.
Patient 2 presented a previously unreported homozygous
c.757G4A mutation, p.A253SfsX30, inherited from her
consanguineous parents. This mutation creates an alteration
of the splicing donor site on the last adenosine of the exon 5,
changing an alanine to a threonine. The expected transcript
product therefore contains a part of intron 5, leading to a
shortened protein due to the occurrence of a stop codon 30
amino acids later (Figure 2).
The pathological effect of these mutations was ascertained
by functional analysis (Table 1) as the two cases exhibited a
near complete loss of CTSC activity.
Conclusion
We describe two previously unreported point mutations,
p.A253SfsX30 and p.G386R, and an intragenic deletion
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Figure 1. CTSC mutation analysis of patient 1. (a) Patient 1 carries a heterozygous mutation c.1156G4C (p.G386R) inherited from her mother.
Electrophoregrams are shown for patient 1 and her parents. The asterisk shows the location of the base transition. (b) Characterization of exons 3–7 deletion
inherited by QMF-PCR. The x-axis displays the computed length of the PCR products in base pairs as determined using an internal standard (ROX350,
Applera). The y-axis shows fluorescence intensities in arbitrary units. Gene fragments are indicated above each peak. Patient 1 fluorogram is in blue, while
the female control is in red. (c) Fluorescence ratios are calculated as indicated in the Materials and Methods section. As an example, the ratio for CTSC exon 4
compared to DSCR1 exon 4 is: patient 1 (CTSC Ex4/DSCR1)/Control (CTSC Ex4/DSCR1)¼ (1088/1587)/(2159/1605)¼ 0.51. Gene dosage anomalies are
in red. Left: fluorescence ratio calculation for patient 1; right: fluorescence ratio calculation for her father. This demonstrates that the deletion was inherited from
the father.
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spanning exons 3–7 that represents a previously unreported
mutational mechanism in CTSC. We propose that such
intragenic deletions should be searched for in patients with
apparent homozygous mutation when one or both parents are
not available for genetic analyses or did not carry the
inherited heterozygous mutation as would be expected. In
the latter situation, false paternity and parental isodisomy
have to be excluded using microsatellite analyses before
performing gene dosage analysis by QMF-PCR.
MATERIALS AND METHODS
Patients
Patient 1 was a 20-year-old Caucasian woman. At age 14 years, she
presented with severe periodontitis and keratoderma. Three years
later, periodontitis and hyperkeratosis worsened to complete teeth
loss and multiple cutaneous abscesses occurred. The diagnosis of
PLS was then proposed and confirmed by molecular analyses. Her
parents were healthy.
Patient 2, a 5-year-old Moroccan girl whose parents were first
cousins, presented with a palmoplantar keratoderma in the first
weeks of life and abnormal decidual tooth loss at the age of 3 years,
associated with severe periodontitis. The parents were healthy.
Informed consent was obtained from patients or parents. This
research followed the tenets of the Declaration of Helsinki
Principles. Institutional approval was not required for experiments.
Mutation analysis of CTSC
PCR and sequencing reaction. The in vitro amplification and
sequencing of all CTSC exons and intron–exon boundaries were
performed as described elsewhere (Toomes et al., 1999; Lefe`vre
et al., 2001). Mutations are described in accordance with the CTSC
cDNA sequence GenBank NM_001814.2. The predicted effect is
based on the protein sequence GenBank NP_001805.1.
QMF-PCR. The seven exons of CTSC were analyzed using a
method adapted from Niel et al. (2004). Primers used for
amplification are available from the authors upon request. In each
set, two external controls were used: DSCR1 exon 4 (located on
chromosome 21) (Solassol et al., 2003) and coagulation factor IX
(FIX) exon 5 (located on chromosome X). Each fragment was
amplified using one primer labeled with the fluorescent phosphor-
amidite 6-FAM dye (Sigma-Aldrich, L’Isle d’Abeau Chesnes, France).
The PCR reactions were performed in duplicate in 25 ml reactions
using the QIAGEN Multiplex PCR kit (Qiagen, Courtaboeuf, France),
with 100ng of genomic DNA and a mix of primers (concentration range
from 0.2 to 0.6mM). The reactions started with an initial denaturation
step of 15minutes at 951C, followed by 23 cycles at 951C for
30 seconds, 551C for 30 seconds, and 721C for 30 seconds, and a
final extension of 7minutes at 721C. After electrophoresis on an ABI
3130XL sequencer (Applera, Courtaboeuf, France), data analysis was
performed with the GeneMapper software (Applera). The results
were first analyzed visually by superimposing fluorograms of patients
and normal controls, normalization being performed with respect to
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Figure 2. CTSC mutation analysis of patient 2. Patient 2, issued from
consanguineous Moroccan parents, carried a homozygous c.757G4A
mutation (p.A253SfsX30), inherited from both parents. This substitution
causes a splice site mutation with the occurrence of a stop codon 30 amino
acids downstream. Electrophoregrams show the homozygous wild-type
sequence (Wt), homozygous-mutated sequence (Mt), and heterozygous status
of both parents. The asterisk shows the location of the base transition.
Table 1. Genetic and functional analyses of patients 1 and 2 and their first-degree relatives
Patients
and relatives Mutations Predicted effect Site Type Status CTSC activity
1 c.1156G4C p.G386R Exon 7 Missense ch 30 (o5%)
Gene deletion exons 3–7 Truncated protein Intragenic deletion
Mother c.1156G4C p.G386R Exon 7 Missense hz 4680 (B80%)
Father Gene deletion exons 3–7 Truncated protein Intragenic deletion hz 5880 (B100%)
2 c.757G4A p.A253SfsX30 Exon 5 Altered splicing hm 0 (o5%)
Mother hz 290 (B20%)
Father hz 395 (B27%)
ch, compound heterozygous mutation; CTSC, cathepsin C; hm, homozygous mutation; hz, heterozygous mutation.
CTSC-specific activity is expressed as nanomoles of NHMec produced per hour and per milligram of cell protein. In brackets, the activity is expressed as
percent of the control values determined in the same experiment. CTSC activity was determined at least in duplicate in control samples, and in quadruplicate
in patients’ samples.
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values obtained with control locus DSCR1. The peak height values
were also imported into a custom Excel spreadsheet, and the copy
number of each fragment was determined by calculating a fluore-
scence ratio for each exon relative to all the other amplified exons in
patients and controls. Theoretical ratios of 1 and 0.5 are expected for a
normal sample and a heterozygous deletion, respectively.
Functional analysis of CTSC
CTSC activity was determined by measuring the amount of NHMec
released by hydrolysis of the synthetic substrate glycyl-L-arginine-7-
amino-4-methylcoumarin (H-gly-arg-NHMec, Bachem, Merseyside,
England) on incubation with sonicated peripheral blood leukocytes,
using the modified protocol of Toomes et al. (1999). Each assay
included controls in which either substrate or sonicated cells were
omitted from the reaction mixture.
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